Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
- 3 February 2011
- journal article
- practice guideline
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 25 (5), 567-620
- https://doi.org/10.1177/0269881110391123
Abstract
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving experts in schizophrenia and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from the participants and interested parties, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. The practice recommendations presented are based on the available evidence to date, and seek to clarify which interventions are of proven benefit. It is hoped that the recommendations will help to inform clinical decision making for practitioners, and perhaps also serve as a source of information for patients and carers. They are accompanied by a more detailed qualitative review of the available evidence. The strength of supporting evidence for each recommendation is rated.Keywords
This publication has 659 references indexed in Scilit:
- Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage SchizophreniaArchives of General Psychiatry, 2010
- Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different DrugsBiological Psychiatry, 2010
- Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic studyEuropean Psychiatry, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Cancer mortality in patients with schizophreniaCancer, 2009
- Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population‐based health dataBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2008
- Cardiac side effects of psychiatric drugsHuman Psychopharmacology: Clinical and Experimental, 2007
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year periodPsychopharmacology, 1989
- Possible teratogenic effect of phenothiazines in human beingsTeratology, 1977